Pharmaceutical Industries
Moderator :

M. Abdelaziz TAZAÏRT

Reporters :
  • M. Abdellah FELLA: Ministry of Industry e
  • M. Malek LAÏDOUNI: Ministry of Participations and Investments Promotion
Preamble
Definition of the pharmaceutical product: « in the sense of the law, pharmaceutical products include medicines, biological reagents, officinal chemicals, galenical products, dressing objects and all other products necessary for human and veterinary medicine » (article 169 law 85-05).
Inventory and statement
The pharmaceutical industry is characterized by:
  • About a hundred of producers (manufacturers and conditioners),
  • More than 70 projects in progress,
  • A national needs coverage at the level of 22 % in value,
  • 78 % of the market covered by the import, that is a value of more than one Thousand million USD,
  • Generics market shares of 25 %.
This industry meets numerous obstacles which slow down its development, among which we can cite:
  • A lack of pharmaceutical product policy,
  • A lack of dialogue between sector professionals and authorities,
  • An ill-adapted regulatory framework.
The pharmaceutical industry has a strategic nature of public health and consequently has to benefit from the State commitment and support.
Recommendations
1.1. Definition and implementation
  • Registrations:
    • Periods: 120 days,
    • Reciprocity in terms of registration fees with foreign countries,
    • Strengthening of local producer right as far as registration is concerned.
  • Repayment: consistency with registration and reference rate,
  • Exemption from Customs duties and VAT of all pharmaceutical products inputs,
  • Exemption from Customs duties and VAT of all pharmaceutical products inputs,
  • Coverage of expired drugs in the country of origin and regularization of physical liabilities.
1.2. Promotion of the national production
  • Protection measures of the national production in accordance with EU - WTO association agreements,
  • Import suspension of products made locally during a probationary period,
  • To make partnership operations easier (transfer of royalties),
  • Policy of generics in particular for the coverage of prevailing pathologies and life time extension,
  • Implementation of a framework for the FDI:
    • Direction towards high technology projects (biotechnology),
    • Accession to foreign markets,
  • To Redeem the Central Pharmacy of Hospitals in its initial prerogatives and associate it with the promotion of local production.
2. Research promotion
  • Development of the partnership universities - companies:
    • Academics integration in boards of directors, scientific councils etc.
    • Taking in charge operators constraints as the subject of thesis or dissertation by academics,
    • To allow the academics to take up posts in companies at the same time as the academic office,
    • The company can be used as practice period ground,
  • Promotion of research and development activity: integration of the various essential qualifications that is to say: chemists, biologists, pharmacists doctors etc. …
  • Development of the partnership in research and development field,
  • Revitalize the activities of vaccines and serum research and production by the Institut Pasteur, on its own or in partnership,
  • Promotion of the innovation by taking in charge the results of the Algerian inventors (forsaken at the moment).
3. Promotion of the human factor
  • Industrial Pharmacy Certificate to be developed,
  • Training for pharmaceutical industry professions, by the creation of a training centre specialized for the needs of the field,
  • Strengthening of operators managerial capabilities for a better competitiveness (organization of professional trainings, recruitment of new qualifications, and use of modern methods of communication).
4. Creation of Medicines Agency
  • Quality control of the pharmaceutical product,
  • Pharmacovigilance and medical devices vigilance,
  • Bioequivalence and clinical tests,
  • Pharmaceutical products registration,
  • Promotion and advertisement monitoring,
  • Inspection of the various concerned groups in the pharmaceutical product chain,
  • Approval and inspections of production units,
  • Publication of the economic information (statistics of the Ministry of Health, Population and Hospital Reform. MSPRH).
5. Creation of a consultation council
  • Participation in the great decisions concerning all the measures likely to have an influence on the pharmaceutical product policy.
  • Composition: Ministry of Health / Ministry of Employment / Ministry of Industry / Ministry of Finance / Ministry of Trade / Ministry of Higher Education / Medicines Agency / Manufacturers
The national producers offer to satisfy 65 % of the market needs by the year 2012, within the framework of the application of these recommendations.
WebServices Technologies